

1 **mTORC1 Restricts Hepatitis C Virus Replication Through ULK1-mediated**
2 **Suppression of miR-122 and Facilitates Post-replication Events**

3

4 Manish Kumar Johri^{1,2}, Hiren Vasantrai Lashkari¹, Dhiviya Vedagiri¹, Divya Gupta¹, and
5 Krishnan Harinivas Harshan^{1,2}#

6

7 ¹CSIR-Centre for Cellular and Molecular Biology, Uppal Road, Hyderabad-500007,
8 India

9 ²Academy of Scientific and Innovative Research (AcSIR), Ghaziabad- 201002, India
10

11

12

13 #Address correspondence to: Krishnan Harinivas Harshan, hkrishnan@ccmb.res.in

14

15

16

17

18

19

20 **ABSTRACT**

21 Mechanistic target of rapamycin (mTOR) is an important kinase that assimilates several
22 upstream signals including viral infection and facilitates appropriate response by the cell
23 through two unique complexes mTORC1 and mTORC2. Here, we demonstrate that
24 mTORC1 is activated early during HCV infection as antiviral response. Pharmacological
25 inhibition of mTORC1 promoted HCV replication as suggested by elevated levels of
26 HCV (+) and (-) RNA strands. This was accompanied by significant drop in extracellular
27 HCV RNA levels indicating defective post-replication stages. The increase in viral RNA
28 levels failed to augment intracellular infectious virion levels, suggesting that mTORC1
29 inhibition is detrimental to post-replication steps. Lower infectivity of the supernatant
30 confirmed this observation. Depletion of Raptor and ULK1 accurately reproduced these
31 results suggesting that mTORC1 imparted these effects on HCV through mTORC1-
32 ULK1 arm. Interestingly, ULK1 depletion resulted in increased levels of miR-122, a
33 critical host factor for HCV replication, thus revealing a new mechanism of regulation by
34 ULK1. The binary effect of mTORC1 on HCV replication and egress suggests that
35 mTORC1-ULK1 could be critical in replication: egress balance. Interestingly we discover
36 that ULK1 depletion did not interfere with autophagy in Huh7.5 cells and hence the
37 effects on HCV replication and post-replication events are not resultant of involvement
38 of autophagy. Our studies demonstrate an overall ULK1 mediated anti-HCV function of
39 mTORC1 and identifies an ULK1-independent autophagy that allows HCV replication in
40 spite of mTORC1 activation.

41

42 Keywords: Hepatitis C Virus, mTOR, Replication, ULK1, miR-122, Autophagy

43

44 INTRODUCTION

45 Hepatitis C Virus (HCV) is the major cause of hepatocellular carcinoma worldwide
46 (Choo et al., 1989). It is the lone member of *Hepacivirus* genus under *Flaviviridae* family
47 and is represented by seven genotypes. HCV spreads through blood or organs and
48 over 170 million people are estimated to have been infected by this pathogen (Hadigan
49 and Kottlilil, 2011), of which over 71 million people worldwide are chronically infected.
50 Conventional combination therapy using pegylated IFN- α and Ribavirin is associated
51 with inconsistent results and causes severe side effects (Fried, 2002; Manns et al.,
52 2006). In the absence of effective vaccines, recently approved direct acting antivirals
53 (DAAs) have shown remarkable success in virus clearance. However, recent studies
54 indicate the emergence of resistant clones against DAAs (Chiara Di Maio et al., 2017;
55 Takeda et al., 2017). Therefore, there is the need for continued efforts for evolving
56 therapeutic regimens to counter the HCV menace.

57 Of the several host factors critical for HCV sustenance, miR-122, a liver enriched
58 miRNA, is indispensable for HCV replication (Jopling et al., 2005). miR-122 is a unique
59 case of miRNA mediated positive regulation, where it binds to the 5' UTR of HCV and
60 stabilizes it (Shimakami et al., 2012). More recent studies suggest that miR-122 does
61 more than providing stability, but is involved in HCV RNA synthesis (Li et al., 2013).
62 Other studies also indicate that miR-122 regulates HCV replication: translation balance
63 (Masaki et al., 2015). It has been demonstrated that simple expression of miR-122

64 renders otherwise non-permissive hepatic cell lines HCV permissive (Kambara et al.,
65 2012).

66 Mechanistic target of Rapamycin (mTOR), a major serine/threonine kinase found in
67 eukaryotes is the target of the versatile drug Rapamycin (Brown et al., 1994; Sabatini et
68 al., 1994). mTOR functions as the catalytic subunit of at least two distinct complexes,
69 mTORC1 and mTORC2 (Saxton and Sabatini, 2017) . mTORC1 is constituted by
70 Raptor, mLST8, PRAS40 and DEPTOR in addition to mTOR (Kim et al., 2002;
71 Wullschleger et al., 2006). mTORC1 is a major signaling hub that regulates several
72 cellular and metabolic activities such as protein translation, autophagy, lipid and nucleic
73 acid biosynthesis. Deregulated mTORC1 signaling is implicated in several cancers
74 (Hsieh et al., 2010; Laplante and Sabatini, 2012). mTORC1 kinase regulates cell
75 functioning by phosphorylating its diverse set of substrates. Of these, eukaryotic
76 translation initiation factor E (eIF4E)-binding protein (4EBP1) is a major substrate that
77 regulates translation initiation (Haghighat et al., 1995). 4EBP1, in its
78 hypophosphorylated form sequesters eukaryotic cap binding protein eIF4E thereby
79 inhibiting cap dependent translation (Richter and Sonenberg, 2005). However, upon
80 phosphorylation by mTORC1, hyperphosphorylated 4EBP1 loses its affinity for eIF4E
81 thereby facilitating translation initiation. Another well-known substrate of mTORC1 is
82 Unc-51 like autophagy activating kinase 1(ULK1) that activates autophagy.
83 Phosphorylation of ULK1 by mTORC1 at S758 residue inhibits autophagy (Egan et al.,
84 2011). Therefore, active mTORC1 can activate translation initiation and suppress
85 autophagy. However, autophagy is a critical requirement for HCV replication (Dreux et

86 al., 2009; Tanida et al., 2009). Activation of mTORC1 could thus be considered as a
87 potential target for HCV replication by limiting autophagy.

88 Whereas a wealth of information exists on mTORC1, reports on the regulation by
89 mTORC2 are far fewer. mTORC2 is constituted by its catalytic subunit mTOR, the
90 Rapamycin-insensitive protein of mTOR (Rictor), mLST8, DEPTOR and mammalian
91 stress-activated MAP kinase-interacting protein 1 (SIN1) (Laplante and Sabatini, 2012).
92 mTORC2 is a tyrosine kinase complex (Sarbasov et al., 2005) that controls cell
93 survival and cellular proliferation by phosphorylating several members of the AGC
94 (PKA/PKG/PKC) family of protein kinases (Saxton and Sabatini, 2017). Rapamycin is
95 known to inhibit mTORC1 exclusively during short-term treatment but can inhibit both
96 complexes C1 and C2 during long-term treatment (Sarbasov et al., 2006). Rapamycin
97 has differential effects on mTORC1 substrates and several cancer lines demonstrate
98 resistance to the drug (Choo et al., 2008). Other important active site inhibitors such as
99 Torin1 (Thoreen et al., 2009) and PP242 (Feldman et al., 2009) inhibit both complexes.
100 The latter drugs potently inhibit protein translation even in Rapamycin resistant systems.
101 mTOR, being a crucial molecule for both translation and autophagy, should be relevant
102 in HCV infection. HCV translation is cap-independent and mediated through internal
103 ribosome entry site (IRES) located in the 5' UTR of its genome (Tsukiyama-Kohara et
104 al., 1992; Wang et al., 1994). Since cap-independent translation is not directly regulated
105 by mTORC1, changes in mTOR could affect host translation, sparing that of HCV. On
106 the other hand, autophagy is critical for HCV replication and establishment of infection.
107 Regardless of its importance, the role of mTOR in HCV infection has been controversial
108 with certain reports suggesting its essentiality in HCV replication (Stohr et al., 2016)

109 while others suggest its antiviral role (Mannova and Beretta, 2005; Shao et al., 2010;
110 Shrivastava et al., 2012). Several factors including cell types, HCV genotype, MOI,
111 experimental set-up (infection vs. transfection) and duration of infection could have
112 contributed to these divergent conclusions. Our previous studies have demonstrated
113 that HCV protein NS5A activated mTORC1 (George et al., 2012). Notwithstanding the
114 differences, it is evident that mTOR is regulated during HCV infection.

115 Previously, we had demonstrated that HCV NS5A activated mTOR and cap complex
116 assembly (George et al., 2012) suggesting that mTOR is activated during HCV
117 infection. In the present study, we sought to understand the role of mTOR in HCV life
118 cycle and identified that activation of mTORC1 by HCV early during infection is an
119 antiviral response by the cells. We identify that mTORC1 restricts HCV replication
120 through ULK1 that further executes the regulation through modulating the levels of miR-
121 122. mTOR inhibition reduced viral titer in the supernatant through slower assembly and
122 packaging of the virions. Our studies demonstrate that mTORC1 is key to the balance
123 between viral replication, virion packaging and release. We also identify a disjunction
124 between ULK1 and autophagy in Huh 7.5 cells thereby explaining simultaneous
125 activation of mTORC1 and autophagy in HCV infected cells. Our results indicate a
126 possible molecular explanation of Huh7.5 being the most efficient system for HCV
127 replication.

128 **Results**

129 ***HCV infection activates mTOR***

130 To investigate the regulation of mTOR upon HCV infection, the kinetics of mTOR activity
131 during HCV infection was studied. Huh7.5 cells infected with 0.5 MOI of HCV gt2a were

132 collected at every 24 hr intervals up to 96 hrs (Figure 1A). HCV infection was confirmed
133 by immunoblotting of viral core protein. mTOR activity was evaluated by measuring
134 phosphorylation of its substrate 4EBP1. Figure 1B and 1C demonstrated that HCV
135 infection caused remarkable mTOR activation at 24 hpi, as compared with the mock,
136 and moderated later on. Since enhanced mTOR activity was detected early during
137 infection, a probable role of mTOR on HCV was further explored.

138 ***mTOR restricts intracellular HCV RNA abundance but augments its***
139 ***extracellular levels***

140 Activation of mTOR in response to HCV infection could possibly be either (i) a host
141 antiviral response to HCV replication; or (ii) facilitating HCV infection. We sought to
142 address these possibilities by inhibiting mTOR using two pharmacological inhibitors of
143 mTOR, Rapamycin and Torin1. While mTOR inhibition restrains host translation, it is
144 expected to spare IRES mediated cap-independent HCV translation using. Huh7.5 cells
145 infected with HCV were inhibited with 25nM Rapamycin/750nM Torin1 for 24 hrs starting
146 at 48 hpi (Figure 2A). Prolonged inhibition was important from a clinical management
147 aspect. Both Rapamycin and Torin1, the latter more strongly, inhibited mTOR in HCV
148 infected cells as indicated by dephosphorylations of 4EBP1 and ULK1 (Figure 2B).
149 Inhibitions in mock-infected cells were also observed (data not shown, as they are
150 irrelevant to the study). We studied their effect on HCV by quantifying intracellular HCV
151 (+) and (-) strand abundance. Completion of HCV replication cycle requires generation
152 of both (+) and (-) strands and hence any consistent change in the levels of both strands
153 is a true reflection of changes in replication rate. mTORC1 inhibition is well known to
154 affect protein homeostasis and stability (Zhao et al., 2015). We chose not to use

155 luciferase based replicon assays due to the possibility that mTORC1 inhibitors might
156 affect the stability and enzyme activity of luciferase.

157 Extensive Torin1 treatment potently induced the levels of HCV (+) and (-) strands
158 (Figure 2C and 2D) and indicated activation of HCV replication. Rapamycin inhibition
159 also caused similar changes in HCV replication (Figure S1A and S1B). Extracellular viral
160 RNA abundance is a measure of HCV particles in the supernatant. Supernatant HCV
161 RNA levels were substantially dropped by Torin1 treatment suggesting that inhibition of
162 mTOR compromises HCV post-replication step such as packaging or egress (Figure
163 2E). Torin1 treatment did not suppress core or NS3 expression suggesting that HCV
164 replication enhancement did not compromise HCV translation, i.e. not a case of
165 replication-translation switching. (Figure 2B, 2F and 2G). These results indicate that
166 mTOR is an important player in balancing intracellular and extracellular HCV RNA
167 levels.

168 ***Low mTOR activity at the time of infection enhances HCV replication***

169 In previous experiments, the role of mTOR was addressed well beyond the peak HCV
170 replication stage. Since mTOR activation occurred during early hours of infection, we
171 sought to learn the effect of mTOR inhibition at the time of infection on HCV. Pre-
172 inhibition mode is also crucial to understand the effect of mTOR inhibition on HCV entry
173 and replication in previously uninfected liver cells when mTOR inhibitors are part of anti-
174 HCV regimen. Huh7.5 cells were pre-inhibited with Torin1 or Rapamycin for 4 hrs and
175 infected with HCV for 4 hrs in presence of the inhibitors (Figure 3A). Viral supernatants
176 with inhibitors were replaced with growth medium and the cells were allowed to grow
177 further for 68 hrs at the end of which viral RNA levels were assayed. From now on, we

178 refer to this as pre-inhibition mode of infection. Inhibitions at the time of infection and
179 after 4 hrs of infection were confirmed in parallel mock-infected sets (Figure S2A and
180 S2B respectively). Interestingly, mTOR remained inhibited even after 68hrs of treatment
181 (Figure 3B), suggesting that mTOR was constantly under suppression throughout the
182 time duration of infection. Similar to 24 hrs inhibition, pre-inhibition of mTOR by Torin1
183 substantially increased HCV RNA levels (Figure 3C and 3D) and caused severe
184 reduction in HCV supernatant RNA (Figure 3E), confirming that prolonged suppression
185 of mTOR boosts HCV replication and impairs viral packaging/egress. As in the earlier
186 case, no remarkable drop in core or NS3 expression was observed during pre-inhibition
187 experiments (Figure 3F and 3G), confirming that HCV translation is unaffected by
188 mTOR inhibition. Higher levels of core detected in prolonged-inhibition could be
189 resultant of dynamics of protein stabilization as this was not obvious in pre-inhibition.
190 Rapamycin treatment caused similar effects on HCV replication, albeit less remarkably
191 (Figure S3A and S3B).

192 **mTOR inhibition suppresses HCV assembly and viral release**

193 To address whether mTOR inhibition affects the viral post-replication steps leading to
194 loss in infectivity, intracellular viral particles extracted from equal number of pre-treated,
195 HCV infected cells used in experiments shown in Figure 3 and their infectivity was
196 tested on naïve Huh7.5 cells. Infectivity between the samples was measured by
197 comparing the HCV RNA levels in the infected cells and their differences were
198 represented as relative infectivity. Notwithstanding the higher RNA presence, infectivity
199 of cellular virions extracted from Torin1 treated cells did not vary from that from DMSO
200 treated samples (Figure 4A). The results suggest that despite augmenting intracellular

201 RNA abundance, Torin1 treatment did not alter the infectious viral particle number.
202 Thus, mTOR inhibition promotes HCV replication but not viral assembly. Next, we
203 tested the infectivity of equal volumes viral supernatants from Torin1 treated cells by
204 infecting naïve cells. This was again measured by relative HCV RNA levels in the
205 infected cells. Interestingly, infectivity of HCV supernatant from Torin1 treated cells was
206 substantially lower as compared with DMSO treated samples (Figure 4B). The drop in
207 infectivity was well comparable with that of HCV RNA levels in supernatants following
208 Torin1 treatment (Figure 3E). Comparable results were observed in prolonged treatment
209 as well (Figure S4A and S4B). This result suggests that the virions released in Torin1
210 treated cells are indeed infectious, but their release into the supernatant is defective.
211 This presented a conundrum because our earlier results suggested that viral assembly
212 seemed unaffected (Figure 4A). However, the drop in supernatant viral particles is a
213 clear indicator of reduced assembly or release. Any inhibition of release, but not
214 assembly, would have resulted in intracellular accumulation of infectious virions leading
215 to increased infectivity by intracellular virions that was not the case (Figure 4A). HCV
216 assembly, packaging and release are integrally associated and our results suggest that
217 mTOR inhibition activated HCV replication and suppressed later events of packaging
218 and release. Further focused studies are required to delineate these processes.
219 mTORC1 is not known to regulate cap-independent translation. In prolonged treatment
220 cases, Torin1 induced core levels while no change was observed in pre-treatment
221 (Figures 2B, 2F, 3B and 3F). Levels of another viral protein, NS3, were unchanged in
222 both conditions (Figures 2B, 2G, 3B and 3G). These findings suggested that mTORC1
223 inhibition did not suppress HCV translation. This was verified by measuring HCV RNA

224 loading in polysome during Torin1 treatment. In contrast to the reduction in polysome
225 size (Figure 4C and 4D), HCV RNA association with the polysomes was enhanced
226 (Figure 4E) by Torin1 pre-treatment, confirming the previous reports that mTOR
227 inhibition does not inhibit IRES translation. Therefore, the drop in HCV RNA and
228 infectivity in the supernatant upon Torin1 treatment is not due to perturbation of HCV
229 translation, but possibly due to assembly and packaging.

230 ***mTORC1, but not mTORC2, restricts intracellular HCV RNA abundance***

231 Torin1 inhibits both mTORC1 and mTORC2. Rapamycin inhibits only mTORC1 during
232 short treatment but can inhibit both mTORC1 and mTORC2 upon extensive treatment.
233 The effect of mTOR inhibition on HCV could have been mediated through either of the
234 mTOR complexes. In order to identify the mTOR complex involved in HCV regulation,
235 we depleted Raptor, a major regulatory component of mTORC1, in Huh7.5 cells by
236 siRNA prior to HCV infection (Figure 5A). Raptor depletion resulted in lower 4EBP1 and
237 ULK1 phosphorylations as expected (Figure 5A). Similar to long-term inhibition with
238 Torin1 and Rapamycin, Raptor depletion induced intracellular HCV RNA levels (Figure
239 5B) and suppressed HCV RNA abundance in the supernatant (Figure 5C). On the
240 contrary, depletion of Rictor, an integral mTORC2 component, had no effect on HCV
241 replication (Figure S5A and S5B). These results confirm that mTOR restricts HCV
242 replication and promotes viral release through mTORC1 but not mTORC2.

243 ***mTORC1 restricts intracellular HCV RNA levels through ULK1***

244 4EBP1 and ULK1 are key substrates of mTORC1. We sought to identify the mTORC1
245 substrate through which mTORC1 regulated HCV replication. Depletion of 4EBP1
246 (Figure S6A and S6B), did not alter HCV replication in Huh7.5 cells, suggesting its

247 dispensability in HCV replication. Next, we analyzed HCV replication in ULK1 depleted
248 Huh7.5 cells. Interestingly, robust ULK1 depletion (Figure 5D) caused significant
249 increase of intracellular (Figure 5E) and severe drop of supernatant HCV RNA levels
250 (Figure 5F), consistent with mTOR inhibition and Raptor depletion. Taken together,
251 these results demonstrate that mTORC1 restricts HCV replication through a mechanism
252 that involves ULK1, but not 4EBP1.

253 ***mTORC1 regulates miR-122 levels through ULK1***

254 Since miR-122 is indispensable for HCV replication, we next enquired its status during
255 mTORC1 inhibitions and knock-downs. Torin1, in both pre-treatment and prolonged
256 treatment resulted in considerable increase in miR-122 levels in HCV infected cells
257 (Figures 6A and S7A respectively) and during ULK1 and Raptor depletions (Figure 6B
258 and S7B respectively). Introduction of anti-miR-122, but not the control anti-miR,
259 efficiently removed miR-122 (Figures 6C and 6D) and caused substantial drop in HCV
260 (+) and (-) strand RNA suggesting that the over-expressed miR-122 was functional
261 (Figures 6E and 6F). HCV translation was suppressed under these conditions as well
262 (Figure 6C). These observations suggest that mTORC1 regulates miR-122 levels
263 through ULK1. These data also suggest that ULK1 has an unidentified role of regulating
264 miR-122 levels through which HCV replication is regulated. These results propose that
265 mTORC1, through ULK1, inhibits miR-122 levels. To the best of our knowledge, this
266 mechanism of regulation of HCV replication is hitherto unidentified.

267 ***Uncoupling of ULK1 with autophagy facilitates maintenance of autophagy even*** 268 ***under mTOR activation***

269 Our results have presented a conundrum since mTORC1 activation would normally
270 suppress autophagy thereby causing a probable inhibition of HCV replication. To
271 address this important point, the status of autophagy was analyzed in Torin1 pre-treated
272 samples described in Figure 3A. Pre-treatment with Torin1 of HCV infected cells
273 induced autophagy, evident from the depleted p62 levels (Figure 7A), thus validating the
274 anti-autophagic role of mTOR. Thus, autophagy activation by Torin1 could be a possible
275 contributor to the enhanced HCV replication. However, this analysis was performed at
276 the end of 72 hours of infection and hence is not a reflection of the status of autophagy
277 at the time, and during the early hours of infection that is critical for establishment of
278 HCV infection. To ascertain this, we treated Huh7.5 cells with Torin1 for 8 hrs, as
279 described in Figure S2B, at the end of which cells were analyzed for autophagy. Not
280 surprisingly, activation of autophagy was also evident at the end of 8 hrs of Torin1
281 treatment without HCV infection (Figure 7B), indicating that this activation could possibly
282 have contributed to the elevated intracellular HCV strands. Similar induction of
283 autophagy was found in prolonged inhibition (Figure 7C). Next, autophagy markers were
284 evaluated in ULK1 depleted cells upon HCV infection. Surprisingly, ULK1 depletion
285 caused no appreciable change in the levels of p62 and Beclin and in LC3 lipidation
286 (Figure 7D-F). To assess the contribution of autophagy in the Torin1 mediated activation
287 of HCV replication, we pre-treated cells with Chloroquine for 6 hrs in presence or
288 absence of Torin1. Treatment was followed by HCV infection for 4 hrs in presence of the
289 inhibitors as indicated above. Chloroquine mediated autophagy inhibition, confirmed by
290 the accumulation of p62 and lipidation of LC3A/B (Figure 7G), caused severe inhibition
291 of HCV replication (Figure 7H). Similar pre-treatment with Bafilomycin also caused

292 substantial drop in HCV RNA abundance (Figure S8), confirming that inhibition of
293 autophagy overrides activation of HCV replication by Torin1. However, since ULK1
294 depletion enhanced HCV replication in the absence of autophagy induction, we propose
295 that autophagy induction during mTORC1 inhibition could be through ULK1 independent
296 mechanisms. We speculate that mTOR mediated restriction on HCV would have been
297 more effective if autophagy was under regulation by ULK1 in this system. Our results
298 demonstrate that mTORC1 restricts HCV replication through ULK1 mediated
299 mechanism without restricting autophagy and this uncoupling allows HCV to flourish in
300 Huh7.5 cells.

301 **DISCUSSION**

302 The current work identifies two critical functions of mTOR on HCV life cycle. On one
303 hand, it restricts HCV replication and on the other, it facilitates steps involved in the
304 assembly of the virions and their release. The dual effects of mTORC1 on HCV are
305 clearly interpreted from the inhibitor and knockdown studies. mTORC1 activation early
306 during HCV infection could have been interpreted either as a pro-viral, pro-growth
307 response or as an antiviral response. Since mTOR restricts HCV replication that
308 precedes the packaging, we conclude that mTOR is part of anti-HCV machinery in
309 hepatoma cells.

310 The increase in (+) strands of HCV following long-term inhibition could be resulted by
311 increased replication rate, by accumulation of viral genome/packaged virions or by
312 replication-translation switch. However, the concurrent increase in the (-) strand of HCV
313 confirmed that mTORC1 inhibition indeed activated its replication. Strand-specific q-RT
314 PCR is a powerful technique in determining the replication status of (+) stand RNA

315 viruses through abundance of (-) strand RNA (Komurian-Pradel et al., 2004; Plaskon et
316 al., 2009; Rance et al., 2012).

317 Effect of mTOR on HCV replication is addressed by previous studies. However,
318 annotating mTOR as a supportive or a suppressive host factor for HCV replication
319 remained debatable. Present study recommends mTOR as an antiviral host factor that
320 limits HCV replication. Our results of HCV mediated suppression of HCV replication
321 corroborate with certain previous report (Mannova and Beretta, 2005) and contradicts
322 with a few others (Huang et al., 2013; Stohr et al., 2016). Several factors including cell
323 types, HCV genotype, MOI, experimental set-up (infection vs. transfection) and duration
324 of infection could have contributed to these divergent conclusions. However, our studies
325 have looked at the role of mTOR comprehensively and used infectious viral system to
326 reach our findings.

327 Infectivity assay using the intracellular virions of Torin1 treated samples from the first
328 step indicates that post replication steps of HCV cycle remain perturbed by mTOR
329 inhibition. Increase in viral replication due to drop in viral translation (replication-
330 translation switch) is shown in many RNA viruses including HCV (Ray and Das, 2011).
331 However, mTOR inhibitions in our study did not depict any drop in HCV core and NS3
332 levels suggesting that mTOR inhibition does not trigger a replication: translation switch
333 in favor of replication by suppressing HCV translation. The increase in intracellular HCV
334 RNA abundance upon mTORC1 inhibition is clearly the outcome of increased
335 replication.

336 Our studies unearthed previously unknown mechanism of regulation of antiviral
337 activities of mTORC1 and identified a new member in this pathway, ULK1. Since ULK1

338 depletion caused activation of miR-122 transcription, it could be suggested that ULK1
339 regulates their transcription. It is possible that ULK1 mediates transcriptional regulation
340 through other molecules or directly involved with their transcription. Nuclear functions of
341 ULK1 have been described recently (Joshi et al., 2016).

342 Egress is a larger process that includes packaging of the genome and its transport
343 through ER-Golgi system before the release takes place. HCV particle assembly is
344 associated with lipid droplets (**Wendel et al.**) in addition, requires factors that are
345 necessary for VLDL assembly and apolipoprotein generation (**Gastaminza et al., 2008;**
346 **Herker et al., 2010**). HCV trafficking is dependent on ER-Golgi trafficking system
347 (**Mankouri et al., 2016**) and microtubule polymerization (**Lai et al., 2010**). Since
348 mTORC1 regulates lipid metabolism (**Laplante and Sabatini, 2009**) and trafficking
349 (**Jiang and Yeung, 2006**), the assembly and trafficking of HCV particles is a likely
350 target of mTORC1 inhibition. In support, recent reports implicate the roles of ULK1 in
351 lipid metabolism (**Ro et al., 2013**) and cytoskeletal rearrangements (**Caino et al., 2013**).

352 At this stage, the mechanistic details on the reduced HCV RNA abundance in the
353 supernatant of mTOR inhibited cells are unclear.

354 mTOR inhibition caused significant cell death in pre-inhibition and prolonged inhibition
355 (Figures S9 A-D). Earlier studies have demonstrated an association between cell
356 division and HCV replication. However, the inhibitory effect of the inhibitors on cell
357 division does not contribute significantly to HCV stages as ULK1 and Raptor knockdown
358 caused similar effects on HCV stages without causing any cell division effects (Figures
359 S9E and S9F).

360 Induction of mTORC1 is antagonistic to autophagy. ULK1 knockdown has been known
361 to block autophagy in HEK293 and MEFs (Chan et al., 2007)Huh7.5 cells is the only
362 known robust infection system for HCV. A single point mutation in the dsRNA sensor
363 retinoic acid-inducible gene-I (RIG-I) proposed to play a role in higher permissiveness
364 for HCV RNA replication (Sumpter et al., 2005). However, we propose that uncoupling
365 of mTORC1 with autophagy facilitated active replication of HCV in Huh7.5 cells. ULK1
366 depletion unquestionably had no effect on autophagy markers in Huh7.5 cells. We
367 hypothesize that though mTORC1 phosphorylates ULK1 during the initial hours of
368 infection, it spares autophagy due to the uncoupling of ULK1 with autophagy. We
369 propose that this could be a major factor that allows high permissivity for HCV in Huh7.5
370 cells. In systems where ULK1 still regulates autophagy, activation of mTOR might
371 effectively suppress autophagy thereby preventing HCV replication. In agreement,
372 Shrivastava et al. identified concurrent activation of autophagy and mTOR (Shrivastava
373 et al., 2012) and concluded that HCV induces autophagy while activation of mTOR
374 facilitated hepatocyte proliferation. Since autophagy seems independent of ULK1 in
375 Huh7.5, HCV is able to maintain its replication even in the presence of activated
376 mTORC1.

377 **Conclusion:** Our studies demonstrate that mTOR is activated during the initial stages
378 of HCV infection. mTOR suppression enhanced HCV RNA titer generated by
379 augmenting replication and hence mTOR activation can be considered as an antiviral
380 response. Simultaneously, mTOR inhibition lowered extracellular HCV levels through
381 suppressing viral package or egress, a feature through which mTOR assumes a virus
382 friendly molecule . mTOR executed these effects through ULK1 and regulated HCV

383 replication through modulating the levels of miR-122. Interestingly, ULK1, though a key
384 molecule in autophagy initiation, does not regulate autophagy in Huh7.5 cells and hence
385 the anti-HCV effects of mTOR could not impart its restriction on HCV replication through
386 inhibiting autophagy. Thus, this uncoupling allows HCV to replicate by utilizing
387 autophagy even in the background of active mTOR.

388 **Experimental procedures**

389 ***Antibodies and inhibitors***

390 All antibodies except p62 and β -Tubulin (Thermo Fischer Scientific) and HCV core
391 (Abcam), were purchased from Cell Signaling Technology. Torin1 was bought from
392 Tocris Bioscience and Rapamycin was from Merck Millipore. Chloroquine and
393 Bafilomycin were from Sigma Aldrich. siRNA pools against RAPTR and ULK1 were
394 from Dharmacon. *4EBP1* and *RICTOR* shRNAs were from Thermo Fisher Scientific.

395 ***Generation of HCVcc particles and titration***

396 Human Hepatoma cell line, Huh7.5 was cultured as described (George et al., 2012).
397 HCV infectious particles were prepared by *in vitro* transcription (IVT) of full-length
398 genome from pFL-J6/JFH1, followed by transfection into Huh7.5 cells (George et al.,
399 2012; Lindenbach et al., 2005). Supernatants from transfected cells were collected,
400 filtered through 0.45 μ m filter and quantified by qRT-PCR by absolute quantification.
401 Briefly, RNA was isolated from viral supernatant and reverse transcribed using HCV RT
402 Rev primer (5'-TGCACGGTCTACGAGACCTC-3'). HCV genome was quantified using
403 HCV SG1F (5'-TATGCCCGGCCATTTGGGCG-3') and HCV SG1R (5'-
404 TACGAGACCTCCCGGGGCAC-3') primers and the viral RNA abundance was
405 estimated as copies/ml.

406 **Primary infection and replication assay by qRT-PCR**

407 Huh7.5 cells were infected with 0.5 MOI of HCV for four hours followed by the
408 replacement of the virus with fresh media until the cells were harvested. HCV (+) and (-)
409 RNA strands were quantified by qRT-PCR. Briefly, infected cells were harvested and
410 total RNA was prepared using Nucleospin RNA kit (Macherey-Nagel). Total RNA from
411 the supernatants was prepared using Trizol (Thermo Fisher Scientific). Total RNA from
412 infected cells or supernatants were converted into cDNA using HCV strand-specific
413 primer (5'-TGCACGGTCTACGAGACCTC-3' for +ve and 5'-
414 ATGAATCACTCCCCTGTGAG-3' for -ve strand). HCV specific regions were amplified
415 from equal amounts of cDNA using SYBR Premix Ex Taq (Takara Bio Inc.) in
416 Lightcycler 480 (Roche Molecular Diagnostics). Fold changes between samples were
417 calculated by using $\Delta\Delta$ Cp values with endogenous GAPDH control.

418 ***HCV infectivity assay***

419 Infectivity of HCV particles from the infected cells or cell supernatants was measured by
420 infecting naïve Huh7.5 cells with them. First, Huh7.5 cells were infected with HCV with
421 Torin1 or DMSO treatment for 72 hrs. For measuring the infectivity of intracellular
422 virions, equal numbers of cells from different treatments were freeze-thawed thrice in
423 serum-free DMEM. Equal volumes of these virion containing media were used to infect
424 naïve Huh7.5 cells for 72 hrs. Subsequently, total RNA was prepared from these
425 infected cells and HCV RNA levels were quantified by qRT-PCR as described earlier.
426 Relative HCV RNA levels are reflection of infectivity of virions from the sample and were
427 plotted in graphs. For measuring the infectivity of supernatants generated from the
428 primary cultures subjected to HCV infection and treatment, equal volumes of the

429 supernatants were used to infect naïve Huh7.5 cells. 72 hrs later, total RNA was
430 prepared as described in earlier sections and HCV RNA was quantified by qRT-PCR.
431 Here again, relative HCV RNA levels represented the infectious viral units in the
432 supernatant and thus graphically represented.

433 ***Real-time quantitative RT-PCR (qRT-PCR)***

434 Total RNA prepared from samples were converted to cDNA using Primescript RT and
435 random hexamer. qPCR was performed using SYBR Premix Ex Taq and gene specific
436 primers. *HNF4A* quantification was described elsewhere (Parveen et al., 2017). miRNAs
437 were prepared using Nucleospin miRNA kit (Macherey-Nagel). miR-122 was quantified
438 using Taqman Gene Expression Assay kits from Thermo Fisher Scientific and
439 normalized against *RNU6B*. All the oligos were procured from Bioserve Bio
440 Technologies. Oligo details are provided in Table S1.

441 ***Immunoblotting***

442 Immunoblotting was performed as described earlier (George et al., 2012). Densitometric
443 analyses of blots were done by using Image J software. Relative phosphorylations were
444 calculated from the ratios of any phosphorylated band to its total protein that was
445 normalized to the corresponding β -Tubulin as loading control (P/T/C).

446 ***Polysome analysis***

447 Polysome profiles of HCV infected cells undergone pre-treatment were prepared as
448 described elsewhere (George et al., 2012). Polysomal fractions from DMSO and Torin1
449 pre-treated HCV infected samples were processed further to prepare polysomal RNA.
450 Briefly, pooled fractions were incubated with 3M sodium acetate and ethanol and RNA
451 was precipitated. To remove Heparin from the preparation, precipitated RNA was

452 incubated with 2.5M lithium chloride for 2 hrs at -30°C . RNA was precipitated at
453 maximum speed and purified using Nucleospin RNA kit (Macherey-Nagel). cDNA
454 synthesis and qRT-PCR was carried as mentioned above.

455 **Statistical analysis of data**

456 All the experiments were performed a minimum of three independent times (unless
457 otherwise specified in figure legends) to generate Mean \pm SEM that are plotted
458 graphically. For statistical significance, paired end, two-tailed t-test was performed and
459 represented as *P*-values. *, ** and *** indicate *P*-values $<0.05>0.01$, $<0.01>0.001$ and
460 <0.001 respectively.

461

462 **Acknowledgements**

463 Special thanks to Mohan Singh and Hitha G Nair for logistic assistance in the laboratory.
464 Giridharan Govindarajan extended assistance with preparation of polysome graph
465 images. This work was supported by the Department of Biotechnology, Govt. of India
466 (BT/PR3975/MED/29/336/2011). M.J. and D.G. received fellowship from University
467 Grants Commission and Council of Scientific and Industrial Research, both under
468 Govt.of India, respectively.

469 **References**

470 Brown, E.J., Albers, M.W., Shin, T.B., Ichikawa, K., Keith, C.T., Lane, W.S., Schreiber, S.L.,
471 1994. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. *Nature* 369,
472 756-758.
473 Caino, M.C., Chae, Y.C., Vaira, V., Ferrero, S., Nosotti, M., Martin, N.M., Weeraratna, A.,
474 O'Connell, M., Jernigan, D., Fatatis, A., Languino, L.R., Bosari, S., Altieri, D.C., 2013. Metabolic
475 stress regulates cytoskeletal dynamics and metastasis of cancer cells. *The Journal of clinical*
476 *investigation* 123, 2907-2920.
477 Chan, E.Y., Kir, S., Tooze, S.A., 2007. siRNA screening of the kinome identifies ULK1 as a
478 multidomain modulator of autophagy. *The Journal of biological chemistry* 282, 25464-25474.
479 Chiara Di Maio, V., Cento, V., Aragri, M., Paolucci, S., Pollicino, T., Coppola, N., Bruzzone, B.,
480 Ghisetti, V., Zazzi, M., Brunetto, M., Bertoli, A., Barbaliscia, S., Galli, S., Gennari, W., Baldanti,

481 F., Raimondo, G., Federico Perno, C., Ceccherini-Silberstein, F., 2017. Frequent NS5A and
482 multiclass resistance in almost all HCV genotypes at DAA failures: what are the chances for
483 second-line regimens? *Journal of hepatology*.
484 Choo, A.Y., Yoon, S.O., Kim, S.G., Roux, P.P., Blenis, J., 2008. Rapamycin differentially inhibits
485 S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. *Proceedings of*
486 *the National Academy of Sciences of the United States of America* 105, 17414-17419.
487 Choo, Q.L., Kuo, G., Weiner, A.J., Overby, L.R., Bradley, D.W., Houghton, M., 1989. Isolation of
488 a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. *Science (New*
489 *York, N.Y.* 244, 359-362.
490 Dreux, M., Gastaminza, P., Wieland, S.F., Chisari, F.V., 2009. The autophagy machinery is
491 required to initiate hepatitis C virus replication. *Proceedings of the National Academy of*
492 *Sciences of the United States of America* 106, 14046-14051.
493 Egan, D., Kim, J., Shaw, R.J., Guan, K.L., 2011. The autophagy initiating kinase ULK1 is
494 regulated via opposing phosphorylation by AMPK and mTOR. *Autophagy* 7, 643-644.
495 Feldman, M.E., Apse, B., Uotila, A., Loewith, R., Knight, Z.A., Ruggero, D., Shokat, K.M., 2009.
496 Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2.
497 *PLoS biology* 7, e1000038.
498 Fried, M.W., 2002. Side effects of therapy of hepatitis C and their management. *Hepatology*
499 (Baltimore, Md.) 36, S237-244.
500 Gastaminza, P., Cheng, G., Wieland, S., Zhong, J., Liao, W., Chisari, F.V., 2008. Cellular
501 determinants of hepatitis C virus assembly, maturation, degradation, and secretion. *Journal of*
502 *virology* 82, 2120-2129.
503 George, A., Panda, S., Kudmulwar, D., Chhatbar, S.P., Nayak, S.C., Krishnan, H.H., 2012.
504 Hepatitis C virus NS5A binds to the mRNA cap-binding eukaryotic translation initiation 4F
505 (eIF4F) complex and up-regulates host translation initiation machinery through eIF4E-binding
506 protein 1 inactivation. *The Journal of biological chemistry* 287, 5042-5058.
507 Hadigan, C., Kottlilil, S., 2011. Hepatitis C virus infection and coinfection with human
508 immunodeficiency virus: challenges and advancements in management. *Jama* 306, 294-301.
509 Haghghat, A., Mader, S., Pause, A., Sonenberg, N., 1995. Repression of cap-dependent
510 translation by 4E-binding protein 1: competition with p220 for binding to eukaryotic initiation
511 factor-4E. *The EMBO journal* 14, 5701-5709.
512 Herker, E., Harris, C., Hernandez, C., Carpentier, A., Kaehlcke, K., Rosenberg, A.R., Farese,
513 R.V., Jr., Ott, M., 2010. Efficient hepatitis C virus particle formation requires diacylglycerol
514 acyltransferase-1. *Nature medicine* 16, 1295-1298.
515 Hsieh, A.C., Costa, M., Zollo, O., Davis, C., Feldman, M.E., Testa, J.R., Meyuhas, O., Shokat,
516 K.M., Ruggero, D., 2010. Genetic dissection of the oncogenic mTOR pathway reveals
517 druggable addiction to translational control via 4EBP-eIF4E. *Cancer cell* 17, 249-261.
518 Huang, H., Kang, R., Wang, J., Luo, G., Yang, W., Zhao, Z., 2013. Hepatitis C virus inhibits
519 AKT-tuberous sclerosis complex (TSC), the mechanistic target of rapamycin (mTOR) pathway,
520 through endoplasmic reticulum stress to induce autophagy. *Autophagy* 9, 175-195.
521 Jiang, X., Yeung, R.S., 2006. Regulation of microtubule-dependent protein transport by the
522 TSC2/mammalian target of rapamycin pathway. *Cancer research* 66, 5258-5269.
523 Jopling, C.L., Yi, M., Lancaster, A.M., Lemon, S.M., Sarnow, P., 2005. Modulation of hepatitis C
524 virus RNA abundance by a liver-specific MicroRNA. *Science (New York, N.Y.)* 309, 1577-1581.
525 Joshi, A., Iyengar, R., Joo, J.H., Li-Harms, X.J., Wright, C., Marino, R., Winborn, B.J., Phillips,
526 A., Temirov, J., Sciarretta, S., Kriwacki, R., Peng, J., Shelat, A., Kundu, M., 2016. Nuclear ULK1
527 promotes cell death in response to oxidative stress through PARP1. *Cell death and*
528 *differentiation* 23, 216-230.
529 Kambara, H., Fukuhara, T., Shiokawa, M., Ono, C., Ohara, Y., Kamitani, W., Matsuura, Y.,
530 2012. Establishment of a novel permissive cell line for the propagation of hepatitis C virus by
531 expression of microRNA miR122. *Journal of virology* 86, 1382-1393.

532 Kim, D.H., Sarbassov, D.D., Ali, S.M., King, J.E., Latek, R.R., Erdjument-Bromage, H., Tempst,
533 P., Sabatini, D.M., 2002. mTOR interacts with raptor to form a nutrient-sensitive complex that
534 signals to the cell growth machinery. *Cell* 110, 163-175.
535 Komurian-Pradel, F., Perret, M., Deiman, B., Sodoeyer, M., Lotteau, V., Paranhos-Baccala, G.,
536 Andre, P., 2004. Strand specific quantitative real-time PCR to study replication of hepatitis C
537 virus genome. *Journal of virological methods* 116, 103-106.
538 Lai, C.K., Jeng, K.S., Machida, K., Lai, M.M., 2010. Hepatitis C virus egress and release depend
539 on endosomal trafficking of core protein. *Journal of virology* 84, 11590-11598.
540 Laplante, M., Sabatini, D.M., 2009. An emerging role of mTOR in lipid biosynthesis. *Current*
541 *biology : CB* 19, R1046-1052.
542 Laplante, M., Sabatini, D.M., 2012. mTOR signaling in growth control and disease. *Cell* 149,
543 274-293.
544 Li, Y., Masaki, T., Lemon, S.M., 2013. miR-122 and the Hepatitis C RNA genome: more than
545 just stability. *RNA biology* 10, 919-923.
546 Lindenbach, B.D., Evans, M.J., Syder, A.J., Wolk, B., Tellinghuisen, T.L., Liu, C.C., Maruyama,
547 T., Hynes, R.O., Burton, D.R., McKeating, J.A., Rice, C.M., 2005. Complete replication of
548 hepatitis C virus in cell culture. *Science (New York, N.Y)* 309, 623-626.
549 Mankouri, J., Walter, C., Stewart, H., Bentham, M., Park, W.S., Heo, W.D., Fukuda, M., Griffin,
550 S., Harris, M., 2016. Release of Infectious Hepatitis C Virus from Huh7 Cells Occurs via a trans-
551 Golgi Network-to-Endosome Pathway Independent of Very-Low-Density Lipoprotein Secretion.
552 *Journal of virology* 90, 7159-7170.
553 Mannova, P., Beretta, L., 2005. Activation of the N-Ras-PI3K-Akt-mTOR pathway by hepatitis C
554 virus: control of cell survival and viral replication. *Journal of virology* 79, 8742-8749.
555 Manns, M.P., Wedemeyer, H., Cornberg, M., 2006. Treating viral hepatitis C: efficacy, side
556 effects, and complications. *Gut* 55, 1350-1359.
557 Masaki, T., Arend, K.C., Li, Y., Yamane, D., McGivern, D.R., Kato, T., Wakita, T., Moorman,
558 N.J., Lemon, S.M., 2015. miR-122 stimulates hepatitis C virus RNA synthesis by altering the
559 balance of viral RNAs engaged in replication versus translation. *Cell host & microbe* 17, 217-
560 228.
561 Parveen, S., Vedagiri, D., Nair, H.G., Parthasarathy, H., Harshan, K.H., 2017. Unconventional
562 MAPK-GSK-3beta Pathway Behind Atypical Epithelial-Mesenchymal Transition In
563 Hepatocellular Carcinoma. *Scientific reports* 7, 8842.
564 Plaskon, N.E., Adelman, Z.N., Myles, K.M., 2009. Accurate strand-specific quantification of viral
565 RNA. *PLoS one* 4, e7468.
566 Rance, E., Tanner, J.E., Alfieri, C., 2012. Inhibition of I kappa B kinase by thalidomide increases
567 hepatitis C virus RNA replication. *Journal of viral hepatitis* 19, e73-80.
568 Ray, U., Das, S., 2011. Interplay between NS3 protease and human La protein regulates
569 translation-replication switch of Hepatitis C virus. *Scientific reports* 1, 1.
570 Richter, J.D., Sonenberg, N., 2005. Regulation of cap-dependent translation by eIF4E inhibitory
571 proteins. *Nature* 433, 477-480.
572 Ro, S.H., Jung, C.H., Hahn, W.S., Xu, X., Kim, Y.M., Yun, Y.S., Park, J.M., Kim, K.H., Seo, M.,
573 Ha, T.Y., Arriaga, E.A., Bernlohr, D.A., Kim, D.H., 2013. Distinct functions of Ulk1 and Ulk2 in
574 the regulation of lipid metabolism in adipocytes. *Autophagy* 9, 2103-2114.
575 Sabatini, D.M., Erdjument-Bromage, H., Lui, M., Tempst, P., Snyder, S.H., 1994. RAFT1: a
576 mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous
577 to yeast TORs. *Cell* 78, 35-43.
578 Sarbassov, D.D., Ali, S.M., Sengupta, S., Sheen, J.H., Hsu, P.P., Bagley, A.F., Markhard, A.L.,
579 Sabatini, D.M., 2006. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB.
580 *Molecular cell* 22, 159-168.
581 Sarbassov, D.D., Guertin, D.A., Ali, S.M., Sabatini, D.M., 2005. Phosphorylation and regulation
582 of Akt/PKB by the rictor-mTOR complex. *Science (New York, N.Y)* 307, 1098-1101.

583 Saxton, R.A., Sabatini, D.M., 2017. mTOR Signaling in Growth, Metabolism, and Disease. *Cell*
584 168, 960-976.

585 Shao, R.X., Zhang, L., Peng, L.F., Sun, E., Chung, W.J., Jang, J.Y., Tsai, W.L., Hyppolite, G.,
586 Chung, R.T., 2010. Suppressor of cytokine signaling 3 suppresses hepatitis C virus replication
587 in an mTOR-dependent manner. *Journal of virology* 84, 6060-6069.

588 Shimakami, T., Yamane, D., Jangra, R.K., Kempf, B.J., Spaniel, C., Barton, D.J., Lemon, S.M.,
589 2012. Stabilization of hepatitis C virus RNA by an Ago2-miR-122 complex. *Proceedings of the*
590 *National Academy of Sciences of the United States of America* 109, 941-946.

591 Shrivastava, S., Bhanja Chowdhury, J., Steele, R., Ray, R., Ray, R.B., 2012. Hepatitis C virus
592 upregulates Beclin1 for induction of autophagy and activates mTOR signaling. *Journal of*
593 *virology* 86, 8705-8712.

594 Stohr, S., Costa, R., Sandmann, L., Westhaus, S., Pfaender, S., Anggakusuma, Dazert, E.,
595 Meuleman, P., Vondran, F.W., Manns, M.P., Steinmann, E., von Hahn, T., Ciesek, S., 2016.
596 Host cell mTORC1 is required for HCV RNA replication. *Gut* 65, 2017-2028.

597 Sumpter, R., Jr., Loo, Y.M., Foy, E., Li, K., Yoneyama, M., Fujita, T., Lemon, S.M., Gale, M., Jr.,
598 2005. Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA
599 replication through a cellular RNA helicase, RIG-I. *Journal of virology* 79, 2689-2699.

600 Takeda, H., Ueda, Y., Inuzuka, T., Yamashita, Y., Osaki, Y., Nasu, A., Umeda, M., Takemura,
601 R., Seno, H., Sekine, A., Marusawa, H., 2017. Evolution of multi-drug resistant HCV clones from
602 pre-existing resistant-associated variants during direct-acting antiviral therapy determined by
603 third-generation sequencing. *Scientific reports* 7, 45605.

604 Tanida, I., Fukasawa, M., Ueno, T., Kominami, E., Wakita, T., Hanada, K., 2009. Knockdown of
605 autophagy-related gene decreases the production of infectious hepatitis C virus particles.
606 *Autophagy* 5, 937-945.

607 Thoreen, C.C., Kang, S.A., Chang, J.W., Liu, Q., Zhang, J., Gao, Y., Reichling, L.J., Sim, T.,
608 Sabatini, D.M., Gray, N.S., 2009. An ATP-competitive mammalian target of rapamycin inhibitor
609 reveals rapamycin-resistant functions of mTORC1. *The Journal of biological chemistry* 284,
610 8023-8032.

611 Tsukiyama-Kohara, K., Iizuka, N., Kohara, M., Nomoto, A., 1992. Internal ribosome entry site
612 within hepatitis C virus RNA. *Journal of virology* 66, 1476-1483.

613 Wang, C., Sarnow, P., Siddiqui, A., 1994. A conserved helical element is essential for internal
614 initiation of translation of hepatitis C virus RNA. *Journal of virology* 68, 7301-7307.

615 Wendel, H.G., Silva, R.L., Malina, A., Mills, J.R., Zhu, H., Ueda, T., Watanabe-Fukunaga, R.,
616 Fukunaga, R., Teruya-Feldstein, J., Pelletier, J., Lowe, S.W., 2007. Dissecting eIF4E action in
617 tumorigenesis. *Genes & development* 21, 3232-3237.

618 Wullschleger, S., Loewith, R., Hall, M.N., 2006. TOR signaling in growth and metabolism. *Cell*
619 124, 471-484.

620 Zhao, J., Zhai, B., Gygi, S.P., Goldberg, A.L., 2015. mTOR inhibition activates overall protein
621 degradation by the ubiquitin proteasome system as well as by autophagy. *Proceedings of the*
622 *National Academy of Sciences of the United States of America* 112, 15790-15797.

623

624

625

626

627

628

629 **FIGURES**

630

631

632

633 **Fig. 1.**

634

635

636

637

638

639

640

641

642

643

644

645

646

647

648

649

650

651

652


653

654

655


656

657




658 **Fig. 2.**

659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686



687 **Fig. 3.**

688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715



716 **Fig. 4.**

717

718

719

720

721

722

723

724

725

726

727

728

729

730

731

732

733

734

735

736

737

738

739

740

741

742

743

744

745

746

747

748

749

750

751

752

753


754

755

756


757

758



759 **Fig. 5.**

760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804



805 **Fig. 6.**

806

807

808

809

810

811

812

813

814

815

816

817

818

819

820

821

822

823

824

825

826

827

828

829

830

831

832

833

834

835

836

837

838

839

840

841

842

843


844

845

846

847

848



849 **Fig. 7.**

850

851

852

853

854

855

856

857

858

859

860

861

862

863

864

865

866

867

868

869

870

871

872

873

874

875


876

877

878

879

880



881

882 **LEGENDS**

884 **Fig. 1. Kinetics of HCV replication and its effect on mTOR activation.** (A)

885 Schematic of HCV infection setup. Huh7.5 cells were infected with HCV at 0.5 MOI for 4

886 hrs after which the infected cells were grown and harvested at every 24 hrs interval. (B)

887 Activation of mTOR during HCV infection in Huh7.5 cells demonstrated by

888 immunoblotting of the infected and mock lysates. (C) Quantification of 4EBP1
889 phosphorylation in HCV infected cells. Densitometric values of phosphorylated 4EBP1
890 bands from HCV infected samples were normalized to that of the total protein and was
891 further normalized to that of β -Tubulin. These values were normalized to that of the
892 mock-infected samples and fold changes were plotted in graph.

893 **Fig. 2. Effect of mTOR inhibition on HCV infection.** (A) Schematic depiction of
894 HCV infection and mTOR inhibition. HCV infected cells were inhibited with either
895 Rapamycin or Torin1 at 48 hpi for 24 hrs, after which the cells were harvested. (B)
896 Immunoblot confirming mTOR inhibition by the two inhibitors. Relative intracellular
897 abundance of (C) (+) and (D) (-) strands of HCV, quantified by qRT-PCR. (E)
898 Extracellular HCV RNA abundance in supernatants of inhibited cells. (F) Relative levels
899 of core and (G) NS3 upon mTOR inhibition from immunoblots.

900 **Fig. 3. Consequence of pre-inhibition of mTOR on HCV infection.** (A) Schematic of
901 mTOR inhibition and HCV infection. Huh7.5 cells were pre-treated with either
902 Rapamycin or Torin1 for 4 hrs prior to HCV infection. At the end of this, cells were
903 infected with HCV in presence of the inhibitors. Subsequently, cells were cultured in
904 fresh media for another 68 hrs at which time they were harvested. (B) Immunoblot
905 validating the inhibition of mTOR. (C) Relative intracellular abundance of HCV (+) and
906 (D) (-) strands, quantified by qRT-PCR. (E) Extracellular HCV RNA levels quantified in
907 supernatants. (F) Relative levels of core and (G) NS3 upon mTOR inhibition from
908 immunoblots.

909 **Fig. 4. HCV post-replication steps are perturbed with Torin1, but not viral protein**
910 **translation** (A) Equal number of HCV infected Huh7.5 cells (primary infection) in the

911 presence of Torin1 or DMSO from Figure 3A were freeze-thawed and the released viral
912 particles were resuspended in equal volumes of serum-free media. This viral
913 suspension was used to infect fresh Huh7.5 cells for 72 hrs (secondary infection) after
914 which intracellular HCV RNA abundance was quantified. Relative HCV (+) strand
915 abundance from Huh7.5 cells infected in the second round, infected with intracellular
916 virus of either Torin1 or DMSO treated cells during the primary infection. (B) Relative
917 HCV (+) strand abundance from Huh7.5 cells infected with the supernatant of Torin1 or
918 DMSO treated cells during the primary infection as shown in Figure 3E. (C) Polysome
919 profiles of HCV infected cells after pre-treatment with Torin1. Cells harvested at 72 hpi
920 in pre-treatment mode were lysed and polysome profiles were generated. (D)
921 Quantitative representation of relative polysome association in Torin1 and DMSO
922 treated cells as described in (C). Area under the polysomal fractions were measured for
923 representation. (E) All the polysome fractions were pooled, RNA was precipitated and
924 relative association of HCV RNA with polysome fractions of Torin1 pre-treated cells
925 against DMSO treated control cells.

926 **Fig. 5. mTORC1 restricts intracellular HCV RNA abundance and facilitates**
927 **extracellular HCV RNA levels through ULK1** (A) Confirmation of Raptor depletion by
928 immunoblotting. Huh7.5 cells were transfected with siRNA pool targeting *RPTOR* or with
929 non-targeting siRNA 18 hrs before infection. 72 hpi, cells were harvested for analysis.
930 (B) Relative intracellular abundance of HCV (+) strands quantified by qRT-PCR. (C)
931 HCV abundance quantified in supernatants. (D) Immunoblotting for confirmation of ULK1
932 depletion. Huh7.5 cells were transfected with siRNA pool targeting *ULK1* or with non-
933 targeting siRNA 18 hrs before infection. 72 hpi, cells were harvested for analysis. (E)

934 Relative intracellular abundance of HCV (+) strands quantified by qRT-PCR. (F) HCV
935 RNA levels quantified in supernatants.

936 **Fig. 6. mTOR restricts miR122 transcription through ULK1** Relative miR-122 levels
937 in HCV infected cells subjected to (A) Torin1 pre-treatment and (B) ULK1 depletion. The
938 miR-122 levels were quantified by Taqman based kits and normalized against *RNU6B*.
939 (C) Effect of anti-miR-122 on ULK1 mediated activation of miR-122 in HCV infection.
940 Confirmation of ULK1 knockdown and HCV infection by immunoblotting. Huh7.5 cells
941 were transfected with siRNA pool targeting *ULK1* or with non-targeting siRNA 18 hrs
942 before infection. 72 hpi, cells were harvested for analysis. 24 hours prior harvesting
943 200uM anti-miR122 was transfected. The miR-122 levels were quantified by Taqman
944 based kits and normalized against *RNU6B*. (D) Quantitation of miR-122 levels after
945 transfecting anti-miR-122 or the control anti-miR. (E) Relative intracellular abundance of
946 HCV (+) strands and (F) (-) strands in the presence of anti-miR-122.

947 **Fig. 7. ULK1 does not regulate autophagy in Huh7.5 cells upon HCV infection.** (A)
948 Analysis of p62 levels following Torin1 treatment of HCV infected Huh7.5 cells in pre-
949 treatment mode by immunoblotting. (B) Evaluation of autophagy activation in Huh7.5
950 cells treated with Torin1 for 8hrs. Cells treated with Torin1 for 8 hrs were harvested to
951 analyze autophagy markers by immunoblotting. (C) HCV infected cells were inhibited
952 with Torin1 as shown in Figure 2. Immunoblot of p62 after 24 hours of Torin1 post-
953 inhibition. (D) Investigation of autophagy in ULK1 depleted Huh7.5 cells upon HCV
954 infection as described in the Figure 5A, by immunoblotting. (E) Graphical representation
955 of relative LC3A/B lipidation and (F) that of p62 levels in samples displayed in Figure
956 7D. (G) Analysis of autophagy in Huh7.5 cells pretreated with Torin1 in presence or

957 absence of Chloroquine, by immunoblotting. Huh7.5 cells were pre-treated with 750nM
958 Torin1 with or without 25 μ M Chloroquine for 6 hrs after which they were both infected
959 with HCV for 4 hrs in the presence of the inhibitors. Post-infection, cells were allowed to
960 grow in fresh media for another 68 hours before harvesting. (H) Graphical
961 representation of relative HCV intracellular (+) strand titers quantified by qRT-PCR. T
962 =Torin1, C=Chloroquine.

963 **Graphical Abstract:** HCV infection activates mTORC1. Activated mTORC1
964 phosphorylates ULK1 that, possibly in association with other factors, suppresses
965 transcription of miR-122. Lower miR-122 levels would in turn affect intracellular HCV
966 RNA abundance. mTORC1 and ULK1 increase abundance of extracellular HCV RNA
967 through unknown mechanisms. Though ULK1 is the prime molecule of autophagy
968 regulation, it does not govern autophagy in Huh7.5 cells.

969